Chargement en cours...
Inhibition of androgen receptor and β-catenin activity in prostate cancer
Androgen receptor (AR) is the major therapeutic target in aggressive prostate cancer. However, targeting AR alone can result in drug resistance and disease recurrence. Therefore, simultaneous targeting of multiple pathways could in principle be an effective approach to treating prostate cancer. Here...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
National Academy of Sciences
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3785716/ https://ncbi.nlm.nih.gov/pubmed/24019458 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1218168110 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|